Brepocitinib Overview & RVT-3101 Update

Consistent Data Supports Highly Compelling Clinical Activity for TLIA Class 45% 40% 35% Clinical Remission (Modified Mayo) ■RVT-3101 Placebo ■Comparator Pbo-adj A = 30% p = 0.02 40% Pbo-adj A 20% = p = 0.01 30% 31% 25% 20% 15% 10% 12% 10% 5% 0% All-Comers Expected P3 Dose Biomarker Positive Expected P3 Dose Placebo Endoscopic Improvement ■RVT-3101 Placebo ■Comparator Placebo 65% 60% Pbo-adj A = 46% p = 0.0005 55% 56% 50% Pbo-adj A=22% 45% p = 0.01 Pbo-adj A 25% 40% 40% 26% 35% 30% 25% 20% 15% 19% 10% 10% 1% 5% 0% PRAO23 All-Comers Expected P3 Dose Biomarker Positive Expected P3 Dose Pbo-adj A 31% 37% PRAO23 6% Figures reflect cross-trial comparison and not results from a head-to-head study. Differences exist between trial designs and subject characteristics, and caution should be exercised when comparing data across studies. • roivant Clinical Remission reported for RVT-3101 requires stool frequency ≤ 1 and 21 point reduction from baseline, rectal bleeding frequency = 0, and endoscopic score ≤ 1 Clinical Remission reported for PRA023 requires stool frequency ≤1 and 20 point reduction from baseline, rectal bleeding frequency = 0, and endoscopic score ≤ 1 11 For investor audiences only

View entire presentation